Analogs of cytochalasin B as radiopharmaceuticals for nuclear im

Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

424 185, 424 189, A61K 4900

Patent

active

054076587

ABSTRACT:
Analogs of cytochalasin B are used as radiopharmaceuticals to provide an image for the nuclear imaging of glucose transport across cell membranes. Like cytochalasin B, the analogs bind specifically to glucose transport protein, and in doing so, serve as markers indicating the amount of glucose transport protein present on the surfaces of cells. The analogs differ from cytochalasin B by the inclusion of a radionuclide in the region of the terminal phenyl group on cytochalasin B, where the radionuclide does not interfere with the binding specificity of the analog. Disclosed herein are such analogs as well as analogs with which readily accept radionuclides at the desired location on the structure, either by conjugation or substitution.

REFERENCES:
patent: 4765972 (1988-08-01), Safa et al.
Thorens et al., "Molecular Physiology of Glucose Transporters," Diabetes Care, vol. 13, (3), Mar. 1990, pp. 209-218.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Analogs of cytochalasin B as radiopharmaceuticals for nuclear im does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Analogs of cytochalasin B as radiopharmaceuticals for nuclear im, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogs of cytochalasin B as radiopharmaceuticals for nuclear im will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-65123

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.